INTEREST GROUP
WMIS COMMUNITY
ABOUT ADDMI
The ADDMI Interest Group addresses the pipeline issue for drug development, encourages and fosters multidisciplinary research towards advancing drug development through Molecular Imaging (ADDMI), provides a platform for productive discussions around drug development through molecular imaging and its challenges, pursues a common goal of developing ADDMI, helps facilitate the successful development of ADDMI, provides a platform to address clinical manufacturing issues and Phase 1 clinical trials, and establishes ADDMI/WMIS as a ‘central body’ to help address regulatory issues related to ADDMI.
Mission Statement
To globally engage and advance discovery and clinical application of molecular imaging approaches for the development of molecular imaging based companion diagnostics for therapeutics.
Strategic Directions
Advance drug development through molecular imaging
- Encourage multidisciplinary research toward clinically validated molecular imaging-based companion diagnostics
- Create opportunities for discussion around development challenges
- Connect academia, industry, CROs, biotech and clinicians
Support successful translation
- Encourage innovative science
- Address clinical manufacturing and Phase I trial challenges
- Help address regulatory and reimbursement issues
Leadership
Ali Azhdarinia, PhD
The University of Texas Health Science Center at Houston
Mohammed Farhoud MSc
Xodus Imaging
Fay Nicolson, PhD
Dana-Farber Cancer Institute
Shil Patel, Ph.D.
Radio Therapeutics, USA
Join a WMIS Community
Connect, collaborate, and get involved with the WMIS communities that fit your interests and goals.
Not a WMIS Member?
Become a WMIS member first to participate in WMIS Communities.